Yazar "Solak, Ibrahim" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim Yok
    Öğe
    Evaluation of 25-Hydroxyvitamin D Levels in Central Anatolia, Turkey
    (Hindawi Ltd, 2018) Solak, Ibrahim; Cihan, Fatma Goksin; Mercan, Seher; Kethuda, Tugba; Eryilmaz, Mehmet Ali
    Background/Aim. The aim of this study is to evaluate serum 25-hydroxyvitamin D levels measured within one year at an Education and Research Hospital in Turkey to identify vitamin D insufficiency/deficiency (which is very commonly seen in the society) and to provide a current approach to treatment management. Materials and Methods. This retrospective descriptive study was carried out by examining the data relating to 35,667 individuals. Results. Of the individuals participating in the study, 94.47% had a serum 25-hydroxyvitamin D level less than 30 ng/ml, 76.25% had a serum 25-hydroxyvitamin D level less than 20 ng/ml, and 32.20% had a serum 25-hydroxyvitamin D level less than 10 ng/ml. The mean serum 25-hydroxyvitamin D level of all individuals included in the study was 15.2 +/- 8.8 ng/ml. The mean serum 25-hydroxyvitamin D level was 14.5 +/- 8.8 ng/ml among women and 18.1 +/- 8.4 ng/ml among men, respectively (p<0.001). Conclusion. Vitamin D deficiency/insufficiency is widespread in the world and in Turkey. The data obtained from this study suggest that without measuring serum 25-hydroxyvitamin D level will be cost-effective in every age group (except for those are at risk of toxicity) as in children aged 0-1 year old in Turkey and that making a decision in this direction will make a great contribution to the economy of the country.
  • Küçük Resim Yok
    Öğe
    Visceral Adiposity Index Levels in Patients with Hypothyroidism
    (Natl Med Assoc, 2018) Pekgor, Selma; Duran, Cevdet; Kutlu, Ruhusen; Solak, Ibrahim; Pekgor, Ahmet; Eryilmaz, Mehmet Ali
    Objective: To assess visceral adiposity index (VAI) as a sign of cardio-vascular diseases (CVD) in hypothyroidism patients and to compare CVD risks in overt or subclinical hypothyroidism patients. Materials and methods: Sixty-eight hypothyroidism patients (29 with overt and 39 with subclinical hypothyroidism) and 33 age- and gender-matched control patients were included. VAI levels were calculated with the following formula: (waist circumference (WC)/[36.58+(1.89xbody mass index (BMI))])x[(triglyceride (TG) (mmol/L)/0.81)x(1.52xhigh-density lipoprotein cholesterol (HDL-cholesterol) (mmol/L))] and (WC/[39.68+(1.88xBMI)])x[(TG (mmol/L)/1.03)x(1.31xHDL-cholesterol (mmol/L))], respectively. Results: While body weight (p < 0.01), BMI (p < 0.01), TG and VAI levels (p < 0.01) were higher in hypothyroidism patients than controls, HDL-cholesterol levels were lower (p = 0.02). When patients were divided to groups as subclinical (n = 39) and overt hypothyroidism (n = 29) and compared with each other and controls (n = 33), body weight (p = 0.02 and p = 0.02, respectively), BMI (p = 0.01 and p < 0.01, respectively) and TG (p < 0.01 and p = 0.03, respectively) were higher in overt and subclinical hypothyroidism groups than controls. HDL-cholesterol was lower only in the group with overt hypothyroidism than controls (p = 0.01). Although found similar to each other in overt and subclinical hypothyroidism groups, VAI levels were observed to be higher in both groups than controls (p < 0.01 and p = 0.02, respectively). In correlation analysis, a positive correlation was determined between thyroid stimulating hormone (TSH), BMI and VAI levels (p = 0.03 and p < 0.01, respectively). Conclusions: Due to the association between increased VAI levels, and metabolic syndrome and CVDs, we consider that several measures should be promptly taken to decrease these risk factors, and further studies with a larger sample size should be performed.